RGNT (Regentis Biomaterials) Operating Margin %: 0.00% (As of Dec. 2025)


RGNT Regentis Biomaterials Ltd RGNT
14 GF Score
Price $4.15
! 2 Warning Signs
View Full Analysis

What is Regentis Biomaterials Operating Margin %?

Regentis Biomaterials RGNT -1.19% 14 Operating Margin % is 0.00% as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Regentis Biomaterials ranks worse than 122548.9% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Regentis Biomaterials's Operating Income for the six months ended in Dec. 2025 was $-8.18 Mil. Regentis Biomaterials's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Regentis Biomaterials's Operating Margin % for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Regentis Biomaterials's Operating Margin % or its related term are showing as below:


RGNT's Operating Margin % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 3.465
* Ranked among companies with meaningful Operating Margin % only.

Regentis Biomaterials's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Regentis Biomaterials's Operating Income for the six months ended in Dec. 2025 was $-8.18 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was $-8.62 Mil.

Warning Sign:

Regentis Biomaterials Ltd had lost money in 67% of the time over the past 3quarters.


Regentis Biomaterials  (AMEX:RGNT) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Regentis Biomaterials Operating Margin % Related Terms


Regentis Biomaterials Operating Margin % Historical Data

* Premium members only.

The historical data trend for Regentis Biomaterials's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regentis Biomaterials Operating Margin % Chart

Regentis Biomaterials Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Regentis Biomaterials Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RGNT vs MHUAF, LUCY, CUPR: Operating Margin % Comparison

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regentis Biomaterials Operating Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's Operating Margin % falls into.


RGNT
14GF Score
Regentis Biomaterials Ltd RGNT
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regentis Biomaterials Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Regentis Biomaterials's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-8.619 / 0
= %

Regentis Biomaterials's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-8.18 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Regentis Biomaterials (RGNT) has a Operating Margin % of 0.00% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Regentis Biomaterials and its competitors. According to the industry distribution chart, Regentis Biomaterials ranks #999999 out of 816 companies in the Medical Devices & Instruments industry.
Is Regentis Biomaterials' Operating Margin % too high?
Regentis Biomaterials' current Operating Margin % is 0.00%. Based on the distribution chart, Regentis Biomaterials ranks #999999 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' Operating Margin % compare to MHUAF and LUCY?
According to the Medical Devices & Instruments industry distribution chart, Regentis Biomaterials ranks #999999 out of 816 companies for Operating Margin %. This places Regentis Biomaterials in the lower half of its industry. The industry median Operating Margin % is 3.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.47, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Regentis Biomaterials and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regentis Biomaterials's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current Operating Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score

Get the complete analysis for RGNT

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.15
Price